The concept of 'bioprospecting' or 'biopiracy' has become a hot topic in recent years. Zoë Clyde-Watson takes a look.
Biopiracy refers to the practice of commercially developing naturally occurring biological materials, such as plant substances or genetic cell lines, by a technologically advanced country or organisation without fair compensation to the peoples or nations in whose territory the materials were originally discovered.
Inevitably, this leads to a conflict of interest between foreign multinationals attempting to enforce IP rights, and developing countries trying to protect their cultural heritage. Many countries with a long history of traditional knowledge are hampered by the fact that very little of it is accessible in written form. Instead, knowledge is simply passed on by word of mouth from one generation to the next, making it incompatible with modern IP laws, both in terms of ownership and prior art effect.
Various initiatives have been adopted in order more fairly to reflect the contribution traditional knowledge makes to the modern world, particularly in the field of medicine. These include creating digital knowledge libraries to ensure that traditional knowledge has a prior art effect, and collaborative projects or benefit-sharing arrangements with local indigenous communities.
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at firstname.lastname@example.org